Anyone searching neladalkib vs lorlatinib will find no head-to-head trial. No published evidence yet shows which drug is better. What the data do show is narrower. The US Food and Drug Administration (FDA) granted accelerated approval to neladalkib, branded Nelkarmi, on 17 November 2026. It covers adults with previously treated ALK-positive non-small cell lung cancer (NSCLC). That places the GSK drug in the second-line setting where Pfizer’s lorlatinib (Lorbrena) has competed since 2018.
What the FDA approved on 17 November
The FDA approval notice for neladalkib names Nuvalent as the sponsor. GSK completed its acquisition of Nuvalent in July 2026. The indication has two parts. First, it covers adults whose disease progressed after one prior ALK tyrosine kinase inhibitor (TKI), alectinib. Second, it covers adults who have had two or more prior ALK TKIs plus platinum-based chemotherapy.
According to GSK, the decision arrived ahead of the original 27 November target action date. The FDA said the application carried priority review, breakthrough therapy and orphan drug designations. The recommended dose is 150 mg once daily. Because the approval is accelerated, it rests on response rates rather than survival data.
GSK’s chief scientific officer, Tony Wood, called Nelkarmi “our second new medicine approved in lung cancer this year”. The first was zidesamtinib (Jideytro), approved in July for previously treated ROS1-positive NSCLC.
What ALKOVE-1 showed after alectinib
The approval rests on ALKOVE-1 (NCT05384626), a single-arm, open-label Phase 1/2 study. Responses were confirmed by blinded independent central review. In 67 patients whose only prior ALK TKI was alectinib, the objective response rate (ORR) was 49 per cent. The 95 per cent confidence interval ran from 37 to 62 per cent. Of those responders, 76 per cent responded for six months or more. For 52 per cent, responses lasted 12 months or more.
In 155 more heavily treated patients, the ORR was 32 per cent (confidence interval 24 to 40 per cent). Responses lasted six months or more in 69 per cent of responders. They lasted 12 months or more in 51 per cent. GSK also reports a 55 per cent intracranial response rate in 20 alectinib-only patients with measurable brain lesions.
Lorlatinib-pretreated patients respond less often
Nuvalent’s November 2025 topline release split the pre-treated population by prior lorlatinib exposure. In 63 lorlatinib-naïve patients, the ORR was 46 per cent. In 190 lorlatinib-pretreated patients, it was 26 per cent, including two unconfirmed partial responses. Intracranial responses followed the same pattern, at 63 per cent versus 21 per cent. These subgroup figures come from an earlier data cut, not from the FDA-reviewed cohorts. Fierce Pharma reported the view of Angel Qin of the University of Michigan, an invited discussant at ASCO 2026. She called the 26 per cent post-lorlatinib response rate “modest”.
Neladalkib vs lorlatinib: what the trials can and cannot show
Lorlatinib’s second-line evidence also came from a single-arm study, B7461001. That 2018 approval was also an accelerated approval. The FDA’s 2018 lorlatinib approval notice reported an ORR of 48 per cent in 215 patients. Those patients had received one or more earlier ALK inhibitors. Median duration of response was 12.5 months. Intracranial ORR was 60 per cent in 89 patients with measurable brain lesions.
On paper, 49 per cent and 48 per cent look similar. However, the populations differ in prior treatment, trial era and the inhibitors already used. Neither trial randomised patients against the other drug. Any neladalkib vs lorlatinib ranking built on these numbers is therefore a cross-trial comparison. Such comparisons cannot establish that one drug is superior.
Lorlatinib also holds a broader label. Its US indication covers adults with ALK-positive metastatic NSCLC, with no prior-treatment requirement. That first-line use rests on the randomised CROWN trial against crizotinib, with a progression-free survival hazard ratio of 0.28. Neladalkib, by contrast, is approved only after prior ALK TKI treatment. Both drugs are taken by mouth once a day. The FDA notices give recommended doses of 100 mg for lorlatinib and 150 mg for neladalkib.
Analysts have still drawn the comparison. In November 2025, Fierce Biotech reported a view from Guggenheim Securities analysts. They said Nuvalent expected neladalkib to prove more durable than Lorbrena across trials. That is a company thesis relayed by one firm’s analysts, not a trial finding.
How the safety profiles differ
On safety, the neladalkib vs lorlatinib contrast is clearer, because it appears on the labels. The current Lorbrena prescribing information, revised January 2026, lists eight warnings and precautions. They include central nervous system (CNS) effects, hyperlipidaemia, atrioventricular block, interstitial lung disease, hypertension and hyperglycaemia. CNS effects occurred in 52 per cent of 476 patients. Cognitive effects affected 28 per cent and mood effects 21 per cent. Lipid-lowering medication was needed in 83 per cent.
Nuvalent says neladalkib was designed to spare the tropomyosin receptor kinase (TRK) family. The company argues this may avoid TRK-related CNS adverse events seen with dual TRK and ALK inhibitors. Neladalkib’s FDA warnings are hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation and embryo-fetal toxicity. Its most common adverse reactions include hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, oedema and fatigue.
The topline safety set covered 656 patients at the recommended dose, with a median exposure of 6.0 months. Raised ALT occurred in 47 per cent and raised AST in 44 per cent. Constipation affected 28 per cent and dysgeusia 23 per cent. Dose reductions for adverse events occurred in 17 per cent, and 5 per cent discontinued. That release did not report CNS adverse event rates. A CNS advantage therefore remains a design rationale, not a measured comparative finding.
When will a randomised answer arrive?
The decisive trial does not involve lorlatinib. ALKAZAR (NCT06765109) is a Phase 3 study randomising about 450 TKI-naïve patients to neladalkib or alectinib. Its primary endpoint is progression-free survival by blinded independent central review, according to Nuvalent. Overall survival and intracranial response are among its secondary endpoints. The UK research summary notes that alectinib is taken twice daily in the comparator arm.
So ALKAZAR will not settle neladalkib vs lorlatinib directly. Neither GSK nor Nuvalent has announced a readout date. ALK Positive UK, a patient charity, lists an expected trial end of December 2029. A search on 19 November 2026 found no announced trial comparing neladalkib directly with lorlatinib.
What it means for UK patients
In the UK, the neladalkib vs lorlatinib question is not yet a practical choice. Neladalkib has no UK marketing authorisation. A search on 19 November 2026 found no MHRA filing announced by either company. Lorlatinib, by contrast, is available on the NHS. NICE recommended it in May 2020 after alectinib or ceritinib, or after crizotinib plus another ALK TKI. The NICE guidance TA1103, published in October 2025, says lorlatinib can be used before any ALK inhibitor. ALK Positive UK notes that NICE would need to approve neladalkib before routine NHS use. For UK readers, the comparison is therefore mainly a US question for now.
UK centres are taking part in ALKAZAR. The Health Research Authority summary for ALKAZAR records a favourable ethics opinion dated 7 May 2025. ALK Positive UK lists The Royal Marsden, Guy’s, Addenbrooke’s and Maidstone Hospital among UK sites. The charity also describes an expanded access programme at the three original ALKOVE-1 hospitals.
What would change the answer
Three developments would sharpen the picture. The first is ALKAZAR’s progression-free survival result against alectinib. The second is longer neladalkib follow-up, including reported CNS adverse event rates. The third is the full US label, which the FDA says will be posted on Drugs@FDA.
Until then, clinicians choosing a drug after alectinib are weighing different evidence bases and different toxicities. The data support no firm ranking of one drug over the other.














